frequent neurodegenerative brain diseases. Its time course is slow and is characterized by progressive loss of dopaminergic and other brainstem neurons resulting in malfunctioning of the cerebral neuronal systems responsible for motor functions. The clinical signs are slowness of movement, muscle rigidity and rest-tremor amongst other features. The cause of the disease is unknown, but recently involvement of genetic factors is being researched. Positron emission tomography (PET) allows in vivo determination of striatai dopaminergic activity. This has increased our insight in the pathophysiology of the disease and permits direct study of disease progression at a biochemical level and equally to monitor whether potential neuroprotective interventions are indeed effective. Thus far no drug has emerged but promising substances are currently being studied.
INTRODUCTION
Parkinson's disease (PD) has for the first time been described in a comprehensive way in 1817 by James Parkinson in an article entitled "An Essay on the Shaking Palsy". The disorder has since then been named after him. The diagnosis PD is made on clinical grounds solely since there does not exist a specific laboratory test to confirm the characteristic cerebral pathological alterations which lie at the basis of this condition. In most cases the clinical pattern of signs and symptoms is sufficiently clear to make the diagnosis with confidence. However, a certain number of patients will pose considerable difficulties as to the correct diagnosis, particularly in early stages of their disease, even for an experienced neurologist.
Overlap with diseases which are not PD, but are accompanied with some form of parkinsonistic features, may occur regularly.
In PD at least two of the three cardinal signs bradykinesia, rigidity and tremorneed to be present (Levy & Cummings, 1999 In this chapter, apart from clinical features, some aspects of the pathophysiology of the disease will be described. In particular the role of positron emission tomography (PET) will be highlighted.
CAUSE
To date the cause of idiopathic Parkinson's disease is still unknown. Accelerated aging has been discussed as a possibility, but is now discarded mainly because the brainstem pathology found in post-mortem PD tissue is clearly different from the patterns of alteration seen with aging . Genetic (Leenders, 1997) . From Fig. 2 (Piccini et al., 1999) . At baseline the concordance for the FDOPA uptake (reduced in the clinically not-affected twin) was significantly higher in the monozygotic (55%) than in the dizygotic twin pairs (18%). The asymptomatic monozygotic cotwins all showed progressive loss of dopaminergic function over seven years and four developed clinical PD. None of the dizygotic twin pairs became clinically concordant. These findings support some role for genetic factors in the causation of PD. However, the expression of genetic susceptibility must be rather varying since the latencies for clinical concordance vary greatly and may last for many decades. Twin studies have appealing characteristics but also a number of pitfalls, for example, the heavy selection bias and the particular biological situation of the subjects involved. Another recent paper studying a large cohort of twins (Tanner et al., 1999) again found no genetic component to be evident when the disease begins after age 50 years. However, genetic factors appear to be important when the disease begins at or before age 50 years.
Disease progression
As PD progresses, specific FDOPA uptake into putamen decreasesthis is a marker that the dopamine-producing cells in the substantia nigra projecting to the putamen are continuing to die with relatively the highest rate of decline in the first years of the disease (see Fig. 2 ).
In Selegiline, a MAO (monoamine oxidase) inhibitor has been extensively tested in, for example, the DATATOP PD study. The basic idea was to block MAO and thus diminish oxidative stress to the dopaminergic system. Selegiline exerts neuroprotection in various cellular and animal models which are independent of MAO-B inhibition but may be related to binding to glyceraldehyde-3-phosphate dehydrogenase (Jenner & Olanow, 1998 (Bjorklund & Svendsen, 2001; Dunnett et al., 2000; Peschanski et al., 1999) .
